Lacidipine porous tablets: Formulation and in vitro characterization

Astrilia L. Estibeiro, Divya Harmalkar, Soraiya Godinho, Lalit Kumar, Rupesh K. Shirodkar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lacidipine (LCDP), a BCS class II drug is used in the treatment of hypertension. Upon oral administration, LCDP shows poor absorption from gastrointestinal tract and undergoes extensive first pass hepatic metabolism. The oral bioavailability of LCDP is 10%. The present study involved the development and characterization of LCDP porous tablets to enhance its solubility and dissolution rate. Tablets were formulated by direct compression method followed by vacuum drying at 40 °C for 6 h. Optimized formulation contained croscarmellose sodium as superdisintegrants and camphor as sublimating agent. Tablets were characterized for post compression parameters. Dissolution was carried out in phosphate buffer pH 6.8 and in pH 1.2 buffer with 0.2% Tween 20. Scanning electron microscopy image revealed the presence of highly porous surface texture. Thus, collectively it can be concluded that porous tablets of LCDP can serve as an alternative for enhancement of drug solubility and release thereby enhancing its bioavailability.

Original languageEnglish
Pages (from-to)1764-1771
Number of pages8
JournalLatin American Journal of Pharmacy
Volume37
Issue number9
Publication statusPublished - 01-01-2018

Fingerprint

Tablets
Solubility
Biological Availability
Buffers
Camphor
Carboxymethylcellulose Sodium
Polysorbates
Vacuum
Electron Scanning Microscopy
Oral Administration
Gastrointestinal Tract
Phosphates
In Vitro Techniques
lacidipine
Hypertension
Liver
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Drug Discovery

Cite this

Estibeiro, A. L., Harmalkar, D., Godinho, S., Kumar, L., & Shirodkar, R. K. (2018). Lacidipine porous tablets: Formulation and in vitro characterization. Latin American Journal of Pharmacy, 37(9), 1764-1771.
Estibeiro, Astrilia L. ; Harmalkar, Divya ; Godinho, Soraiya ; Kumar, Lalit ; Shirodkar, Rupesh K. / Lacidipine porous tablets : Formulation and in vitro characterization. In: Latin American Journal of Pharmacy. 2018 ; Vol. 37, No. 9. pp. 1764-1771.
@article{dfed5e02159342eb9aeaf6f6d9c00249,
title = "Lacidipine porous tablets: Formulation and in vitro characterization",
abstract = "Lacidipine (LCDP), a BCS class II drug is used in the treatment of hypertension. Upon oral administration, LCDP shows poor absorption from gastrointestinal tract and undergoes extensive first pass hepatic metabolism. The oral bioavailability of LCDP is 10{\%}. The present study involved the development and characterization of LCDP porous tablets to enhance its solubility and dissolution rate. Tablets were formulated by direct compression method followed by vacuum drying at 40 °C for 6 h. Optimized formulation contained croscarmellose sodium as superdisintegrants and camphor as sublimating agent. Tablets were characterized for post compression parameters. Dissolution was carried out in phosphate buffer pH 6.8 and in pH 1.2 buffer with 0.2{\%} Tween 20. Scanning electron microscopy image revealed the presence of highly porous surface texture. Thus, collectively it can be concluded that porous tablets of LCDP can serve as an alternative for enhancement of drug solubility and release thereby enhancing its bioavailability.",
author = "Estibeiro, {Astrilia L.} and Divya Harmalkar and Soraiya Godinho and Lalit Kumar and Shirodkar, {Rupesh K.}",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "37",
pages = "1764--1771",
journal = "Latin American Journal of Pharmacy",
issn = "0326-2383",
publisher = "Colegio de Farmaceuticos de la Provincia de Buenos Aires",
number = "9",

}

Estibeiro, AL, Harmalkar, D, Godinho, S, Kumar, L & Shirodkar, RK 2018, 'Lacidipine porous tablets: Formulation and in vitro characterization', Latin American Journal of Pharmacy, vol. 37, no. 9, pp. 1764-1771.

Lacidipine porous tablets : Formulation and in vitro characterization. / Estibeiro, Astrilia L.; Harmalkar, Divya; Godinho, Soraiya; Kumar, Lalit; Shirodkar, Rupesh K.

In: Latin American Journal of Pharmacy, Vol. 37, No. 9, 01.01.2018, p. 1764-1771.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lacidipine porous tablets

T2 - Formulation and in vitro characterization

AU - Estibeiro, Astrilia L.

AU - Harmalkar, Divya

AU - Godinho, Soraiya

AU - Kumar, Lalit

AU - Shirodkar, Rupesh K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Lacidipine (LCDP), a BCS class II drug is used in the treatment of hypertension. Upon oral administration, LCDP shows poor absorption from gastrointestinal tract and undergoes extensive first pass hepatic metabolism. The oral bioavailability of LCDP is 10%. The present study involved the development and characterization of LCDP porous tablets to enhance its solubility and dissolution rate. Tablets were formulated by direct compression method followed by vacuum drying at 40 °C for 6 h. Optimized formulation contained croscarmellose sodium as superdisintegrants and camphor as sublimating agent. Tablets were characterized for post compression parameters. Dissolution was carried out in phosphate buffer pH 6.8 and in pH 1.2 buffer with 0.2% Tween 20. Scanning electron microscopy image revealed the presence of highly porous surface texture. Thus, collectively it can be concluded that porous tablets of LCDP can serve as an alternative for enhancement of drug solubility and release thereby enhancing its bioavailability.

AB - Lacidipine (LCDP), a BCS class II drug is used in the treatment of hypertension. Upon oral administration, LCDP shows poor absorption from gastrointestinal tract and undergoes extensive first pass hepatic metabolism. The oral bioavailability of LCDP is 10%. The present study involved the development and characterization of LCDP porous tablets to enhance its solubility and dissolution rate. Tablets were formulated by direct compression method followed by vacuum drying at 40 °C for 6 h. Optimized formulation contained croscarmellose sodium as superdisintegrants and camphor as sublimating agent. Tablets were characterized for post compression parameters. Dissolution was carried out in phosphate buffer pH 6.8 and in pH 1.2 buffer with 0.2% Tween 20. Scanning electron microscopy image revealed the presence of highly porous surface texture. Thus, collectively it can be concluded that porous tablets of LCDP can serve as an alternative for enhancement of drug solubility and release thereby enhancing its bioavailability.

UR - http://www.scopus.com/inward/record.url?scp=85053789036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053789036&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85053789036

VL - 37

SP - 1764

EP - 1771

JO - Latin American Journal of Pharmacy

JF - Latin American Journal of Pharmacy

SN - 0326-2383

IS - 9

ER -

Estibeiro AL, Harmalkar D, Godinho S, Kumar L, Shirodkar RK. Lacidipine porous tablets: Formulation and in vitro characterization. Latin American Journal of Pharmacy. 2018 Jan 1;37(9):1764-1771.